Bristol-myers Squibb Compnay

Viiv Healthcare UK (no.5) Limited

Viiv Healthcare UK Limited

Zhong Yang

John A Bender

John F Kadow

Nicholas A Meanwell

Makonen Belema

Robert G Gentles

Piyasena Hewawasam

Gan Wang

Annapurna Pendri

Van N Nguyen

Yong Tu

Brett R Beno

Kap-Sun Yeung

Omar D Lopez

Jeffrey Lee Romine

Denis R St Laurent

Alan Xiangdong Wang

Ying Han

Guo Li

Qi Chen

Robert A Fridell

Tao Wang

Zhongxing Zhang

Owen Brendan Wallace

Min Ding

Katharine A Grant-Young

Kyle J Eastman

Rico Lavoie

Manoranjan Panda

Srinivasan Thangathirupathy

Michael J Smith

Ningning Xu

Shirong Zhu

Rajesh Onkardas Bora

Selvakumar Kumaravel

Mallikarjuna Rao Mettu

John A Easter

Bao-Ning Su

Shilpa Maheshwarappa Holehatti

Denis R STLAURENT

Piyasena Hewasam

JohnF Kadow

JohnA Bender

NicholasA Meanwell

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: 

Inhibitors of human immunodeficiency virus replication

Compounds of Formula I with activity against HIV, including pharmaceutical compositions and methods for using these compounds in treating human immunodeficiency virus (HIV) infection, are set forth: 

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C virus inhibitors

The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. 

Aromatic heterocyclic fused indolobenzadiazepine HCV NS5B inhibitors

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. 

Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. I.

Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. 

Compounds for the treatment of Hepatitis C

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. 

Pyrrolidine fused indolobenzadiazepine HCV NS5B inhibitors

The invention comprises substituted diazaindole-dicarbonyl-piperazinyl derivatives of general Formula I wherein:  compositions thereof and their use for treating HIV infection.

Diazaindole-dicarbonyl-piperazinyl antiviral agents

The invention encompasses compounds of Formula I, pharmaceutically acceptable salts thereof, compositions, and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. 

Compounds for the treatment of hepatitis C

Growing community of inventors

Southington, CT, United States of America

Zhong Yang